KemPharm (KMPH) reported Q3 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $2.97 million.
KemPharm (KMPH) reported Q3 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $2.97 million.